Oral Hypoxia–Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD

BACKGROUND AND OBJECTIVES: Roxadustat (FG-4592), an oral hypoxia–inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin J Am Soc Nephrol
Prif Awduron: Provenzano, Robert, Besarab, Anatole, Sun, Chao H., Diamond, Susan A., Durham, John H., Cangiano, Jose L., Aiello, Joseph R., Novak, James E., Lee, Tyson, Leong, Robert, Roberts, Brian K., Saikali, Khalil G., Hemmerich, Stefan, Szczech, Lynda A., Yu, Kin-Hung Peony, Neff, Thomas B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Nephrology 2016
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4891748/
https://ncbi.nlm.nih.gov/pubmed/27094610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06890615
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg